Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Cancer Biological Therapy Market will achieve 6% CAGR to cross $100bn by 2023

Global Market Insights,Inc.
Posted on: 15 Nov 17
Cancer Biological Therapy Market will achieve 6% CAGR to cross $100bn by 2023 Japan cancer biologic therapy market share accounted for over 40% of the Asia Pacific revenue in 2015, propelled by significant geriatric population base and continue to grow at lucrative CAGR till 2023.

PR Newswire

OCEAN VIEW, Del., Nov. 15, 2017

OCEAN VIEW, Del., Nov. 15, 2017 /PRNewswire-iReach/ -- The Industry growth report "Cancer Biological Therapy MarketBy Product (Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bi-Specific Monoclonal Antibodies], Vaccines [Preventive, Therapeutic], Cancer Growth Blockers [Tyrosine Kinase Inhibitors, Proteasome Inhibitors, mTOR Inhibitors], Blood Cell Growth Factors [Lenograstim, Filgrastim], Cytokines [Interferons, Interleukins]), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023" by Global Market Insights, Inc. forecast Cancer Biological Therapy Market share is anticipated to exceed $100 billion by 2023.

Rising incidence rates and increased adoption of biologic therapy will drive global cancer biological therapy market size. According to WHO estimates, the number of new cancer cases are projected to rise by 70% in the next two decades, largely due to increased consumption of alcohol and tobacco. It is estimated by the ACS that 180,890 prostate cancer and 246,660 breast cancer cases will be diagnosed in 2016 in the U.S.

Mounting global geriatric population is predicted to boost cancer biological therapy market size owing to correlation between new cases and old age. Elderly population is more prone to the disease and according to ACS, 86% of cases in the U.S. were recorded in individuals aged 50 and above. High associated cost attributed to the cost of drug development may act as a major bottleneck to growth. Millions of dollars are spent in identifying a potent drug, obtaining its preclinical data and carry out its clinical trials. Monopoly is yet another factor that contributes to higher cost. The emergence of new therapeutic classes with reduced adverse-effects, such as immuno-oncologics will change the industry landscape.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/676

Cancer vaccines market was over USD 1.9 billion in 2015. Approval of the first vaccine sipuleucel-T (Provenge) for metastatic prostate cancer by the FDA will boost growth in the immunotherapy segment. Cancer growth blockers market was over USD 18 billion in 2015, and is expected to grow at 5.8% CAGR from 2016 to 2023. Tyrosine kinase inhibitors dominated revenue share among the growth blockers in 2015 and is expected to continue witnessing steady growth.

Monoclonal antibodies market size was over USD 21 billion in 2015. Antibody therapy has been the most successful and important approach for treatment of hematological malignancies and solid tumors. Bispecific monoclonal antibodies are anticipated to grow at 6.5% CAGR from 2016 to 2023.

Browse key industry insights spread across 90 pages with 60 market data tables & 47 figures & charts from the report, "Cancer Biological Therapy Market" in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/cancer-biological-therapy-market

U.S. cancer biological therapy market share was over 80% of the North American revenue in 2015, and is anticipated to grow owing to increased public funding for R&D and other government initiatives.

Germany revenue was over USD 4 billion in 2015 and contributes largely to the Europe cancer biological therapy market size. Major drivers include favorable insurance and public reimbursement policies. For instance, about 90% of the German population is covered by 'Statutory Health Insurance' and only 10% of population by private insurance players.

China will drive Asia Pacific cancer biology therapy market share by providing favorable growth opportunities to players, which will motivate them to invest in R&D of biologic products. The favorable reimbursement plans will further accelerate growth.

Key players include Novartis International AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Eli Lilly, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation are some notable companies vying for global cancer biological therapy market share.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/676

Key players include Novartis International AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG, Eli Lilly, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc., Celgene Corporation are some notable companies vying for global cancer biological therapy market share.

Browse Related Reports:

Lung Cancer Diagnostics Market Size 2017 – 2024

Lung Cancer Diagnostics Market share is projected to experience significant growth from 2017 to 2024. Lung cancer diagnostics market size should witness significant growth due to increased prevalence of smoking and exposure to second hand smoke, influencing the occurrence rate of lung malignancies.

https://www.gminsights.com/industry-analysis/lung-cancer-diagnostics-market

Cancer Profiling Market Size 2017 – 2024

Cancer Profiling Market share is projected to experience significant growth from 2017 to 2024. Rising prevalence of cancer worldwide and huge funding available for oncology research are the major factors driving global cancer profiling market growth.

https://www.gminsights.com/industry-analysis/cancer-profiling-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com
Web: https://www.gminsights.com
Blog:https://www.gminsights.com/blogs
Connect with us: Facebook | Google+ | LinkedIn | Twitter

Media Contact: Arun Hegde, Global Market Insights, Inc., +13028467766, sales@gminsights.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Global Market Insights, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 15/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.